Single Nucleotide Polymorphism (SNP) Genotyping Market

Single Nucleotide Polymorphism (SNP) Genotyping Market Overview

The global single nucleotide polymorphism (SNP) genotyping market is expected to grow from USD 12.9 billion in 2025 to USD 61.1 billion by 2035, representing a CAGR of 16.84% during the forecast period.

To learn more about this report, request a free sample copy

Single nucleotide polymorphism genotyping or SNP genotyping is a process of identification and analyzing variations within DNA sequence of an individual at a single base pair. These single nucleotide polymorphisms act as a biomarker to locate genes that are correlated with diseases. When single nucleotide polymorphism occurs in the gene, it may indicate the disease and affect the gene’s function. With rising risk of genetic, chronic and rare diseases, this SNP genotyping is widely adopted for disease diagnosis by locating disease-associated genes. It is worth mentioning that single nucleotide polymorphism is an emerging as a significant area of interest in research, pharmaceuticals and agricultural biotechnology field.

However, single nucleotide polymorphism plays a vital role in pharmaceuticals and research field as it helps to analyze disease and response of a patient towards medication. By using SNP genotyping, researchers can gain better understanding of disease prognosis, drug discovery and treatment planning to improve patient outcome with a personalized approach. In addition to drug designing, single nucleotide polymorphism genotyping has also played a significant role in oncological studies to facilitate treatment of cancer.

Several other factors that are driving the market includes shift towards, genomics, precision medicine (including oncology precision medicine), increasing usage of next-generation sequencing and emerging demand for SNP genotyping for pharmacogenomics. With increasing preferences of next generation sequencing or analysis of SNP for disease diagnosis, several pharmaceutical companies are making considerable investments for technological advancements and adoption of next-generation therapies. For instance, in November 2024, Autoimmunity BioSolutions recently raised USD 2 million in Series Seed funding round to advance development of next generation, immuno-corrective therapy to treat patients with autoimmune disease. The development of next generation involves single nucleotide polymorphism genotyping and next generation sequencing for designing therapy.  

Moreover, the industry players are extensively making efforts to support translational research across the globe. It is important to highlight here that in October 2024, Agilent Technologies and National University of Singapore launched NUS-Agilent Center of Excellence in Cell Metabolism, in order to offer xCELLigence, BioTek and Seahorse XF technologies that will support targeted and untargeted metabolic profiling.  Considering these ongoing initiatives and investments for next generation technologies (especially by next generation sequencing services providers), we believe that single nucleotide polymorphism (SNP) genotyping market remain progressive during the forecast period, offering unprecedented opportunities for innovations.

Single Nucleotide Polymorphism (SNP) Genotyping Market Segmentation Insights

The market research report presents an in-depth analysis companies that are involved in global SNP genotyping industry, across different segments, as defined in the table below:

Single Nucleotide Polymorphism (SNP) Genotyping Market: Report Attributes / Market Segmentation

One of the key objectives of the single nucleotide polymorphism (SNP) genotyping market report was to estimate the current size, opportunity and the market growth potential, over the forecast period, till 2035. We have provided informed estimates on the likely evolution of the market for the forecast period.

The market analysis also features the likely distribution of the current and forecasted opportunity within the market distributed across various segments such as type of technology (polymerase chain reaction, Nezt generation sequencing, microarrays and GeneChips, Taqman Allelic Discrimination, SNP pyrosequencing, SNPlex genotyping system, Sequemon MassArray Maldi-TOF, and other technologies), type of product (consumables, instruments and services), type of application (diagnostic research, pharmacogenomics, agricultural biotechnology, breeding and animal livestock) and geographical region (North America, Europe, Asia Pacific, Middle East and North Africa, and Latin America) and leading players .

In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of industry’s evolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. The financial figures mentioned in this market report are in USD, unless otherwise specified.

Single Nucleotide Polymorphism (SNP) Genotyping Market Share Insights

Market Share by Type of Technology

Based on the type of technology, the global single nucleotide polymorphism (SNP) genotyping market is segmented into polymerase chain reaction, Next generation sequencing, microarrays and GeneChips, Taqman allelic discrimination, SNP pyrosequencing, SNPlex genotyping system, sequemon MassArray Maldi-TOF mass spectrometry, and other technologies. According to our projection, SNP pyrosequencing technology currently holds the highest share (nearly 35%) of the market. This dominance is due to the fact that SNP pyrosequencing technology offer higher flexibility, parallel processing and accuracy in analysis of single nucleotide or gene. Further, with growing incidence of chronic diseases, there is a high demand for SNP pyrosequencing for individualized sequencing of genes, which further supported the growth of this technology.

However, it is important to highlight here that next generation sequencing is anticipated to grow at a higher CAGR during the forecast period. Next generation sequencing is gaining traction to the growing usage in academic research, disease diagnosis, and drug development. Furthermore, next generation sequencing play a significant role in epigenetic modification, and gene profiling, making it an exceptional tool for pharmaceutical in drug designing and development.

Market Share by Type of Product

Based on the type of product, the single nucleotide polymorphism (SNP) genotyping market is segmented into consumables, products and services. According to our projection, currently consumables hold the highest share of the market. This can be attributed to the fact that consumables such as kits, reagents and other laboratory supplies are highly essential for the analysis of single nucleotide polymorphism analysis and genotyping. However, in the long run, instruments and services are likely to grow at a substantial CAGR during the forecast period. This lucrative growth is likely to be the result of growing demand for SNP instruments in ongoing drug research and clinical applications.

However, it is important to highlight here that instruments are expensive and require skilled personnels for seamless operations. Owing to the capital-intensive nature, services segment also register a higher CAGR during the forecast period.

Market Share by Type of Application

The global market is distributed across various types of applications, such as diagnostic research, pharmacogenomics, agricultural biotechnology, breeding and animal livestock. Among these, currently pharmacogenomics holds the largest single nucleotide polymorphism (SNP) genotyping market share (38%) and the trend is likely to remain unchanged during the forecast period. This can be attributed to the increasing demand for precision medicine for the treatment of broad range of diseases. SNP genotyping is highly effective in identifying effects of drug response and certain genes. However, in the long run, diagnostic research is likely to grow at a higher CAGR during the forecast period. Single nucleotide polymorphism (SNP) genotyping technologies such as polymerase chain reaction, next generation sequencing, SNP pyrosequencing and microarrays are currently being utilized for diagnostic research for the development of drugs and understanding of disease progression.

Market Share by Geographical Regions

Based on the geographical region, the global single nucleotide polymorphism (SNP) genotyping market is distributed into North America, Europe, Asia Pacific, Middle East and North Africa, and Latin America. According to our projection, North America accounts for the highest share (close to 35%) of the market. North America has a robust healthcare infrastructure and established players who are presently focusing on advancing genotyping technologies and drug research.

However, in Asia-Pacific, the market for SNP genotyping is expected to grow at a substantial CAGR during the forecast period. This is primarily due to the higher adoption of genome sequencing technologies for a variety of applications including drug discovery, research, diseases studies and more. Furthermore, several industrial leaders has taken strategic initiatives and joint forces for introducing advanced single nucleotide polymorphism (SNP) genotyping technologies. For instance, in October 2024, MGI and OncoDNA collaborated to offer laboratories a streamlined NGS workflow for the implementation of (CGP) comprehensive genomic profiling OncoDEEP® kit in clinical practice.

Single Nucleotide Polymorphism (SNP) Genotyping Market Dynamics

The “Single Nucleotide Polymorphism (SNP) Genotyping Market Report: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, market size and future opportunities for manufacturers of cell therapies, during the forecast period. Further, the report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the market report are briefly discussed below.

Single Nucleotide Polymorphism (SNP) Genotyping Market Competitive Landscape

Currently, the market landscape of single nucleotide polymorphism (SNP) genotyping is competitive, featuring several well-established and new entrants. In order to leverage the competitive edge, the industrial players are focusing on technological innovations and partnerships aiming to expand their product portfolio. For instance, in January 2024, Themo Fisher Scientific introduced Axiom PangenomiX Array (claimed to be the biggest genealogically varied array). It offers maximum genetic cover for pharmacogenomic study and public scale disease research.  Overall, the market seems well-fragmented, featuring the presence of several small, mid-sized and large companies with required expertise to manufacture single nucleotide polymorphism (SNP) genotyping technologies.

Market Drivers: Rapid Incidence in Chronic Conditions Propel The Demand for SNP Genotyping

One of the significant single nucleotide polymorphisms (SNP) genotyping market driver is rising incidence of chronic diseases such as diabetes and cancer. According to the National Cancer Institute, in 2024, nearly 14,910 children and adolescents aged (0-19 years) will be diagnosed with cancer. This alarming increase in cancer incidence has necessitated the requirement of precision medicine to target cancerous cells while eliminating the risk of off-target effects. SNP genotyping in this instance helps in the development of personalized medicine by offering detailed analysis of single gene, making it a potential tool in cancer treatment. In addition to pharmaceutical, the expanding usage of SNP genotyping in agriculture for biotechnology advancements has further contributed to the growth of the market.

Market Restraints: High Cost and Limited Sensitivity of SNP Arrays

Some of the potential single nucleotide polymorphism (SNP) genotyping market challenges includes high cost associated with technologies installation and maintenance. In addition, the single nucleotide polymorphisms genotyping has low or limited sensitivity that may create challenges in detecting balanced translocations within the genome and differentiating abnormalities. Moreover, single nucleotides variations sometimes remain undetected even after performing arrays. In order to increase the adoption of SNP genotyping technologies, key players are required to develop advanced sensitive SNP genotyping technologies with higher sensitivity.

Market Trends: Expanding Applications and Technological Innovations

Single nucleotide polymorphism (SNP) genotyping market trends that are anticipated to grow the industry include expanding applications and technological innovations. Currently, SNP genotyping is being utilized across various industrial sectors including agriculture and biotechnology. For instance, in agriculture sector, SNP genotyping play a significant role in marker-assisted breeding programs to develop high-performing crop varieties, making it an exceptional tool to understand genetic profile in crops. Furthermore, SNP genotyping is also utilized for the identification of disease resistance genes allowing researcher to develop disease free varieties. In addition to expanding application across diverse industries, technological advancements has contributed to the growth of the market during the projected period.

Single Nucleotide Polymorphism (SNP) Genotyping Market Size Analysis

The global SNP genotyping market is currently valued at USD 12.9 billion. Driven by the growing preferences for personalized medicine and targeted therapies, this market is estimated to reach USD 61.1 billion by 2035, representing a higher CAGR of 16.84% during the forecast period. It is important to highlight here that North America is currently dominating the market due to the increasing research on advanced drug formulations to treat broad range of diseases. SNP genotyping technologies, such as polymerase chain reaction, Taqman allelic discrimination, SNP pyrosequencing, applied biosciences SNPlex are helpful to analyze single gene profile. The information collected from the genotyping helps in the formulation of precision drugs.

Leading Companies in Single Nucleotide Polymorphism (SNP) Genotyping Market

Examples of the key players (which have also been profiled in this report) involved in SNP genotyping market includes (in alphabetic order) 10x Genomics, Agilent Technologies, Agena Bioscience, Bio-Rad Laboratories, BGI, Douglas Scientific, Fluidigm, Illumina, Novogene, Oxford Nanopore Technologies, Pacific Biosciences, QIAGEN, Roche and Thermo Fisher Scientific. This market report includes an easily searchable excel database of all the companies focusing on the development of SNP genotyping solutions.

Recent Development in Single Nucleotide Polymorphism (SNP) Genotyping Market

Several recent developments have taken place in the field. We have outlined some of these recent initiatives below.

• In November 2024, Novo Holdings announced its plan to acquire Benchmark Genetics, from Benchmark Holdings.
• In October 2024, MGI announced the collaboration with OncoDNA for the development of OncoDEEP® kits. This innovation solution offers sequencing, secondary analysis, and final interpretation of NGS data (OncoKDMTM).
• In the same month, Twist Bioscience announced the launch of the FlexPrep™ ultra-high throughput library preparation kit. This library preparation kit has been designed with a proprietary twist-developed enzyme to accelerate the adoption of next generation sequencing by microarray users for genome analysis in agriculture field and humans. Notably, it has the capability to profile more than tens of thousands to million of genome samples in parallel goes beyond single nucleotide polymorphisms, require next generation sequencing solution, enabling sequencing at a very reasonable cost.
• In July 2024, Bio-Rad Laboratories announced the launch of the ddSEQTM Single-Cell 3' RNA-Seq Kit and Omnition v1.1 analysis software for single-cell transcriptome and gene expression research.